The DOI matches its Crossref record.
Phage–Antibiotic Synergy Enhances Biofilm Eradication and Survival in a Zebrafish Model of Pseudomonas aeruginosa Infection
Abstract
Pseudomonas aeruginosa is a gram-negative opportunistic pathogen that poses a significant threat due to its increasing multidrug resistance, particularly in clinical settings. This study aimed to isolate and characterize a novel bacteriophage, phiLCL12, from hospital wastewater and evaluate its potential in combination with antibiotics to combat P. aeruginosa infections and biofilm formation. Transmission electron microscopy revealed that phiLCL12 possesses a long contractile tail. The isolated phage exhibited a broad host range of 82.22% and could adsorb up to 98% of its target within 4 min. It was effective against multidrug-resistant strains at both high and low multiplicities of infection (MOIs) levels in lysis tests. Taxonomic classification was determined using PhaGCN2 and Whole genomic analysis, and the results identified phiLCL12 as a member of the Pbunavirus. In vitro experiments demonstrated that phiLCL12 significantly enhanced biofilm clearance and inhibited biofilm formation when combined with sub-inhibitory concentrations of imipenem. Furthermore, in vivo experiments using a zebrafish model showed that phage–antibiotic synergy (PAS) improved survival rate compared to antibiotic treatment alone. This study demonstrates that phiLCL12 is effective in both eradicating and preventing P. aeruginosa biofilm formation. The combination of phiLCL12 and imipenem provides a synergistic effect, significantly enhancing survival outcomes in a zebrafish model. These findings highlight the potential of phage–antibiotic synergy as a promising therapeutic strategy against biofilm-associated infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro and in vivo models that include zebrafish and murine airway and implant systems show accelerated clearance and improved survival, with reduced emergence of resistance [213,214,215].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [215]
In the citing paper
“Phage antibiotic combinations often outperform either alone.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 66
- Wheater, 1980, Pseudomonas aeruginosa and Escherichia coli in sewage and fresh water, Water Res., 14, 713, 10.1016/0043-1354(80)90245-6 · DOI
- Walker, 2015, Pseudomonas aeruginosa in hospital water systems: Biofilms, guidelines, and practicalities, J. Hosp. Infect., 89, 324, 10.1016/j.jhin.2014.11.019 · DOI
- Meier, 2023, An intensive care unit outbreak with multi-drug-resistant Pseudomonas aeruginosa—Spotlight on sinks, J. Hosp. Infect., 139, 161, 10.1016/j.jhin.2023.06.013 · doi:10.1016/j.jhin.2023.06.013
- Mahmoud, S.F., Fayez, M., Swelum, A.A., Alswat, A.S., Alkafafy, M., Alzahrani, O.M., Alsunaini, S.J., Almuslem, A., Al Amer, A.S., and Yusuf, S. (2022). Genetic Diversity, Biofilm Formation, and Antibiotic Resistance of Pseudomonas aeruginosa Isolated from Cow, Camel, and Mare with Clinical Endometritis. Vet. Sci., 9. · DOI
- Kour, 2023, A new strategy to treat Pseudomonas aeruginosa infected burn wounds: Antimicrobial cocktails as potent topical therapy, Med. Hypotheses, 180, 111167, 10.1016/j.mehy.2023.111167 · DOI
- Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies, Biotechnol. Adv., 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
- Reis, 2013, Pseudomonas aeruginosa infection in patients with cystic fibrosis: Scientific evidence regarding clinical impact, diagnosis, and treatment, J. Bras. Pneumol., 39, 495, 10.1590/S1806-37132013000400015 · DOI
- Tredget, 1992, Epidemiology of infections with Pseudomonas aeruginosa in burn patients: The role of hydrotherapy, Clin. Infect. Dis., 15, 941, 10.1093/clind/15.6.941 · doi:10.1093/clind/15.6.941
- Yin, R., Cheng, J., Wang, J., Li, P., and Lin, J. (2022). Treatment of Pseudomonas aeruginosa infectious biofilms: Challenges and strategies. Front. Microbiol., 13. · DOI
- Kadirvelu, 2024, A review on antimicrobial strategies in mitigating biofilm-associated infections on medical implants, Curr. Res. Microb. Sci., 6, 100231
- Omwenga, E.O., and Awuor, S.O. (2024). The Bacterial Biofilms: Formation, Impacts, and Possible Management Targets in the Healthcare System. Can. J. Infect. Dis. Med. Microbiol., 2024. · DOI
- Sahoo, 2024, Biofilm Formation in Chronic Infections: A Comprehensive Review of Pathogenesis, Clinical Implications, and Novel Therapeutic Approaches, Cureus, 16, e70629
- Jean, S.-S., Harnod, D., and Hsueh, P.-R. (2022). Global Threat of Carbapenem-Resistant Gram-Negative Bacteria. Front. Cell. Infect. Microbiol., 12. · DOI · Paper page
- Karlowsky, 2023, Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021, J. Glob. Antimicrob. Resist., 34, 106, 10.1016/j.jgar.2023.06.013 · doi:10.1016/j.jgar.2023.06.013
- Jean, 2022, Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018, J. Microbiol. Immunol. Infect., 55, 463, 10.1016/j.jmii.2021.07.015 · DOI
- Ayobami, 2022, Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: A systematic review and meta-analysis, Emerg. Microbes Infect., 11, 443, 10.1080/22221751.2022.2030196 · DOI · Paper page
- Naddaf, 2024, 40 million deaths by 2050: Toll of drug-resistant infections to rise by 70, Nature, 633, 747, 10.1038/d41586-024-03033-w · DOI
- Chegini, Z., Khoshbayan, A., Vesal, S., Moradabadi, A., Hashemi, A., and Shariati, A. (2021). Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: A narrative review. Ann. Clin. Microbiol. Antimicrob., 20. · DOI
- Hetta, H.F., Rashed, Z.I., Ramadan, Y.N., Al-Kadmy, I.M.S., Kassem, S.M., Ata, H.S., and Nageeb, W.M. (2023). Phage Therapy, a Salvage Treatment for Multidrug-Resistant Bacteria Causing Infective Endocarditis. Biomedicines, 11. · DOI
- Lin, 2017, Phage therapy: An alternative to antibiotics in the age of multi-drug resistance, World J. Gastrointest. Pharmacol. Ther., 8, 162, 10.4292/wjgpt.v8.i3.162 · DOI · Paper page
- Li, 2021, A combination therapy of Phages and Antibiotics: Two is better than one, Int. J. Biol. Sci., 17, 3573, 10.7150/ijbs.60551 · DOI · Paper page
- Łusiak-Szelachowska, M., Międzybrodzki, R., Drulis-Kawa, Z., Cater, K., Knežević, P., Winogradow, C., Amaro, K., Jończyk-Matysiak, E., Weber-Dąbrowska, B., and Rękas, J. (2022). Bacteriophages and antibiotic interactions in clinical practice: What we have learned so far. J. Biomed. Sci., 29. · DOI · Paper page
- Segall, 2019, Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy, Curr. Opin. Microbiol., 51, 46, 10.1016/j.mib.2019.03.005 · DOI
- Siddell, 2023, Virus taxonomy and the role of the International Committee on Taxonomy of Viruses (ICTV), J. Gen. Virol., 104, 001840, 10.1099/jgv.0.001840 · DOI
- Akrami, 2024, High prevalence of multidrug-resistant Pseudomonas aeruginosa carrying integron and exoA, exoS, and exoU genes isolated from burn patients in Ahvaz, southwest Iran: A retrospective study, Health Sci. Rep., 7, e2164, 10.1002/hsr2.2164 · DOI
- Pooladi, 2016, Presence of exoU and exoS Genes in Pseudomonas aeruginosa Isolated from Urinary Tract Infections, Infect. Epidemiol. Med., 2, 8, 10.18869/modares.iem.2.2.8 · doi:10.18869/modares.iem.2.2.8
- Nicas, 1985, Role of exoenzyme S in chronic Pseudomonas aeruginosa lung infections, Eur. J. Clin. Microbiol., 4, 175, 10.1007/BF02013593 · doi:10.1007/bf02013593
- Rutherford, 2018, Environmental reservoirs for exoS+ and exoU+ strains of Pseudomonas aeruginosa, Env. Microbiol. Rep., 10, 485, 10.1111/1758-2229.12653 · doi:10.1111/1758-2229.12653
- Wdowiak, M., Paczesny, J., and Raza, S. (2022). Enhancing the Stability of Bacteriophages Using Physical, Chemical, and Nano-Based Approaches: A Review. Pharmaceutics, 14. · DOI
- Ly-Chatain, M.H. (2014). The factors affecting effectiveness of treatment in phages therapy. Front. Microbiol., 5. · DOI · Paper page
- Florensa, 2022, ResFinder—An open online resource for identification of antimicrobial resistance genes in next-generation sequencing data and prediction of phenotypes from genotypes, Microb. Genom., 8, 000748
- Kleinheinz, 2014, Applying the ResFinder and VirulenceFinder web-services for easy identification of acquired antibiotic resistance and E. coli virulence genes in bacteriophage and prophage nucleotide sequences, Bacteriophage, 4, e27943, 10.4161/bact.27943 · DOI · Paper page
- Yukgehnaish, K., Rajandas, H., Parimannan, S., Manickam, R., Marimuthu, K., Petersen, B., Clokie, M.R.J., Millard, A., and Sicheritz-Pontén, T. (2022). PhageLeads: Rapid Assessment of Phage Therapeutic Suitability Using an Ensemble Machine Learning Approach. Viruses, 14. · DOI · Paper page
- Naville, 2011, ARNold: A web tool for the prediction of Rho-independent transcription terminators, RNA Biol., 8, 11, 10.4161/rna.8.1.13346 · DOI · Paper page
- Sampaio, 2019, Predicting promoters in phage genomes using PhagePromoter, Bioinformatics, 35, 5301, 10.1093/bioinformatics/btz580 · doi:10.1093/bioinformatics/btz580
- Jiang, J.Z., Yuan, W.G., Shang, J., Shi, Y.H., Yang, L.L., Liu, M., Zhu, P., Jin, T., Sun, Y., and Yuan, L.H. (2023). Virus classification for viral genomic fragments using PhaGCN2. Brief. Bioinform., 24. · DOI
- Min, 2020, Phage-Antibiotic Synergy Is Driven by a Unique Combination of Antibacterial Mechanism of Action and Stoichiometry, mBio, 11, e01462-20, 10.1128/mBio.01462-20 · DOI · Paper page
- Kamal, 2015, Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): Antibiotics stimulate lytic phage activity, Appl. Environ. Microbiol., 81, 1132, 10.1128/AEM.02850-14 · DOI · Paper page
- Ghafoor, 2011, Role of exopolysaccharides in Pseudomonas aeruginosa biofilm formation and architecture, Appl. Environ. Microbiol., 77, 5238, 10.1128/AEM.00637-11 · DOI · Paper page
- Feltman, 2001, Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa, Microbiology, 147 Pt 10, 2659, 10.1099/00221287-147-10-2659 · DOI · Paper page
- Zhuo, 2010, Clinical significance of virulence-related genes of type III secretion system of Pseudomonas aeruginosa, Zhonghua Shao Shang Za Zhi Zhonghua Shaoshang Zazhi Chin. J. Burns, 26, 354
- Horna, G., Amaro, C., Palacios, A., Guerra, H., and Ruiz, J. (2019). High frequency of the exoU+/exoS+ genotype associated with multidrug-resistant “high-risk clones” of Pseudomonas aeruginosa clinical isolates from Peruvian hospitals. Sci. Rep., 9. · DOI
- Khashei, 2015, The Frequency of Exotoxin A and Exoenzymes S and U Genes Among Clinical Isolates of Pseudomonas aeruginosa in Shiraz, Iran, Int. J. Mol. Cell. Med., 4, 167
- Song, 2023, Emergence of hypervirulent Pseudomonas aeruginosa pathotypically armed with co-expressed T3SS effectors ExoS and ExoU, hLife, 1, 44, 10.1016/j.hlife.2023.02.001 · DOI
- Ceyssens, 2009, Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa, Environ. Microbiol., 11, 2874, 10.1111/j.1462-2920.2009.02030.x · DOI
- Garbe, J., Wesche, A., Bunk, B., Kazmierczak, M., Selezska, K., Rohde, C., Sikorski, J., Rohde, M., Jahn, D., and Schobert, M. (2010). Characterization of JG024, a Pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions. BMC Microbiol., 10. · DOI
- Sharma, S., Datta, S., Chatterjee, S., Dutta, M., Samanta, J., Vairale, M.G., Gupta, R., Veer, V., and Dwivedi, S.K. (2021). Isolation and characterization of a lytic bacteriophage against Pseudomonas aeruginosa. Sci. Rep., 11. · DOI
- Rezk, N., Abdelsattar, A.S., Elzoghby, D., Agwa, M.M., Abdelmoteleb, M., Aly, R.G., Fayez, M.S., Essam, K., Zaki, B.M., and El-Shibiny, A. (2022). Bacteriophage as a potential therapy to control antibiotic-resistant Pseudomonas aeruginosa infection through topical application onto a full-thickness wound in a rat model. J. Genet. Eng. Biotechnol., 20. · DOI
- Liu, Y., Yao, Z., Mao, Z., Tang, M., Chen, H., Qian, C., Zeng, W., Zhou, T., and Wu, Q. (2024). Quorum sensing gene lasR promotes phage vB_Pae_PLY infection in Pseudomonas aeruginosa. BMC Microbiol., 24. · doi:10.1186/s12866-024-03349-7
- Cui, J., Shi, X., Wang, X., Sun, H., Yan, Y., Zhao, F., Zhang, C., Liu, W., Zou, L., and Han, L. (2023). Characterization of a lytic Pseudomonas aeruginosa phage vB_PaeP_ASP23 and functional analysis of its lysin LysASP and holin HolASP. Front. Microbiol., 14. · doi:10.3389/fmicb.2023.1093668
- Schrader, 1997, Bacteriophage infection and multiplication occur in Pseudomonas aeruginosa starved for 5 years, Can. J. Microbiol., 43, 1157, 10.1139/m97-164 · doi:10.1139/m97-164
- Chegini, Z., Khoshbayan, A., Taati Moghadam, M., Farahani, I., Jazireian, P., and Shariati, A. (2020). Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review. Ann. Clin. Microbiol. Antimicrob., 19. · DOI · Paper page
- Ratner, L. (2019). Biomarkers and Preclinical Models for Adult T-Cell Leukemia-Lymphoma Treatment. Front. Microbiol., 10. · DOI
- Engeman, E., Freyberger, H.R., Corey, B.W., Ward, A.M., He, Y., Nikolich, M.P., Filippov, A.A., Tyner, S.D., and Jacobs, A.C. (2021). Synergistic Killing and Re-Sensitization of Pseudomonas aeruginosa to Antibiotics by Phage-Antibiotic Combination Treatment. Pharmaceuticals, 14. · DOI
- Fong, S.A., Drilling, A., Morales, S., Cornet, M.E., Woodworth, B.A., Fokkens, W.J., Psaltis, A.J., Vreugde, S., and Wormald, P.J. (2017). Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients. Front. Cell. Infect. Microbiol., 7. · DOI · Paper page
- Comeau, A.M., Tétart, F., Trojet, S.N., Prère, M.F., and Krisch, H.M. (2007). Phage-Antibiotic Synergy (PAS): Beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE, 2. · DOI
- Uchiyama, 2018, Piperacillin and ceftazidime produce the strongest synergistic phage—Antibiotic effect in Pseudomonas aeruginosa, Arch. Virol., 163, 1941, 10.1007/s00705-018-3811-0 · doi:10.1007/s00705-018-3811-0
- Kim, 2018, Phage-Antibiotic Synergy via Delayed Lysis, Appl. Environ. Microbiol., 84, e02085-18, 10.1128/AEM.02085-18 · doi:10.1128/aem.02085-18
- Gawish, 2013, An investigation of type 3 secretion toxins encoding-genes of Pseudomonas aeruginosa isolates in a University Hospital in Egypt, J. Microbiol. Infect. Dis., 3, 116, 10.5799/ahinjs.02.2013.03.0093 · doi:10.5799/ahinjs.02.2013.03.0093
- Paranos, P., Pournaras, S., and Meletiadis, J. (2024). A single-layer spot assay for easy, fast, and high-throughput quantitation of phages against multidrug-resistant Gram-negative pathogens. J. Clin. Microbiol., 62. · doi:10.1128/jcm.00743-24
- Aziz, R.K., Bartels, D., Best, A.A., DeJongh, M., Disz, T., Edwards, R.A., Formsma, K., Gerdes, S., Glass, E.M., and Kubal, M. (2008). The RAST Server: Rapid annotations using subsystems technology. BMC Genom., 9. · DOI · Paper page
- Lowe, 1997, tRNAscan-SE: A program for improved detection of transfer RNA genes in genomic sequence, Nucleic Acids Res., 25, 955, 10.1093/nar/25.5.955 · DOI · Paper page
- Lagesen, 2007, RNAmmer: Consistent and rapid annotation of ribosomal RNA genes, Nucleic Acids Res., 35, 3100, 10.1093/nar/gkm160 · DOI · Paper page
- 2017, VICTOR: Genome-based phylogeny and classification of prokaryotic viruses, Bioinformatics, 33, 3396, 10.1093/bioinformatics/btx440 · DOI · Paper page
- Altaf, 2019, In vitro Biofilm Development and Enhanced Rhizosphere Colonization of Triticum aestivum by Fluorescent pseudomonas sp., J. Pure Appl. Microbiol., 13, 1441, 10.22207/JPAM.13.3.14 · doi:10.22207/jpam.13.3.14
- Tsai, 2023, Therapeutic effect and anti-biofilm ability assessment of a novel phage, phiPA1-3, against carbapenem-resistant Pseudomonas aeruginosa, Virus Res., 335, 199178, 10.1016/j.virusres.2023.199178 · DOI
Cited by
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Metadata
- Authors
- Lin, L.-C., Tsai, Y.-C., & Lin, N.-T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-06-01
- Volume
- 26
- Issue
- 11
- Pages
- 5337
- ISSN
- 1422-0067
- Cited by
- 22
- References
- 0
- Language
- en
- Funders
- Tzu Chi University (TCMRC-P-111005)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phage–Antibiotic Synergy Enhances Biofilm Eradication and Survival in a Zebrafish Model of Pseudomonas aeruginosa Infection. https://app.cochat.ai/papers/10.3390/ijms26115337
- The paper
- Lin, L.-C., Tsai, Y.-C., & Lin, N.-T. (2025). Phage–Antibiotic Synergy Enhances Biofilm Eradication and Survival in a Zebrafish Model of Pseudomonas aeruginosa Infection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.